Oric Pharmaceuticals Inc. (ORIC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ORIC Stock Price Chart Interactive Chart >
ORIC Price/Volume Stats
|Current price||$6.13||52-week high||$9.93|
|Prev. close||$5.85||52-week low||$2.36|
|Day high||$6.18||Avg. volume||426,994|
|50-day MA||$4.69||Dividend yield||N/A|
|200-day MA||$3.91||Market Cap||242.61M|
Oric Pharmaceuticals Inc. (ORIC) Company Bio
Oric Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Most Popular Stories View All
ORIC Latest News Stream
|Loading, please wait...|
ORIC Latest Social Stream
View Full ORIC Social Stream
Latest ORIC News From Around the Web
Below are the latest news stories about ORIC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORIC as an investment opportunity.
A share of ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) closed at $5.92 per share on Friday, up from $5.67 day before. While ORIC Pharmaceuticals Inc. has overperformed by 4.41%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ORIC fell by -55.29%, with highs and lows ranging from $13.74 […]
ORIC Pharmaceuticals Inc. (NASDAQ:ORIC)’s traded shares stood at 0.51 million during the last session. At the close of trading, the stock’s price was $5.92, to imply an increase of 4.41% or $0.25 in intraday trading. The ORIC share’s 52-week high remains $13.74, putting it -132.09% down since that peak but still an impressive 60.14% since … After Sinking 4.78% During Past Week, Is ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) Still A Buy? Read More »
Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Development candidate selected for PLK4 synthetic lethal breast cancer program Cash and investments of $228 million expected to fund operating plan into first half of 2025 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage o
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M.
As of Friday, ORIC Pharmaceuticals Inc.’s (NASDAQ:ORIC) stock closed at $5.89, up from $5.28 the previous day. While ORIC Pharmaceuticals Inc. has overperformed by 11.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ORIC fell by -62.22%, with highs and lows ranging from $16.76 to $2.36, […]
ORIC Price Returns